Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and were PD-(L)1 Experienced Achieved Significant Tumor Volume Reductions and Prolonged Progression Free Survival ...

Patients in the pembrolizumab group also tended to have better quality of life based on a symptom score calculated from the seven items of the Lung Cancer Subscale of the Functional Assessment of ...

Neoadjuvant pembrolizumab with chemotherapy led to greater pathologic regression based on percent residual volume tumor vs ...

then pembrolizumab alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer. Pembrolizumab, also known as Keytruda, is given as an infusion and is a monoclonal antibody which ...

in a review of the topic at the recent World Conference on Lung Cancer. But how does a large molecule, like pembrolizumab, reach the brain? The blood-brain barrier, which is composed of tightly ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 ...

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...

An ad-hoc analysis found a higher rate of severe and life-threatening infections in patients with RET-mutant lung cancer ...

Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...

A significant aspect influencing this decision is the positive updated data from the Phase 2 basket study of IO102-IO103 in combination with pembrolizumab, which showed an overall response rate of 55% ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...